These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38908858)

  • 1. Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma.
    Zhao L; Ren Y; Zhang G; Zheng K; Wang J; Sha H; Zhao M; Huang R; Kang D; Su X; Wu Y; Zhang W; Lai R; Li L; Mei R; Wang Y; Tian Y; Wang F; Liu B; Zou Z
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    Lan C; Shen J; Wang Y; Li J; Liu Z; He M; Cao X; Ling J; Huang J; Zheng M; Zou G; Yan H; Liu Q; Yang F; Wei W; Deng Y; Xiong Y; Huang X
    J Clin Oncol; 2020 Dec; 38(34):4095-4106. PubMed ID: 33052760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
    Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study.
    Lan C; Lu H; Zhou L; Liao K; Liu J; Xie Z; Liang H; Zou G; Yang T; Xu Q; Huang X
    Cancer Commun (Lond); 2024 Jun; 44(6):654-669. PubMed ID: 38741375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
    Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
    J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
    Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial.
    Cheng H; Zong L; Kong Y; Wang X; Gu Y; Cang W; Zhao J; Wan X; Yang J; Xiang Y
    Lancet Oncol; 2021 Nov; 22(11):1609-1617. PubMed ID: 34624252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
    Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
    Chen X; Wu X; Wu H; Gu Y; Shao Y; Shao Q; Zhu F; Li X; Qian X; Hu J; Zhao F; Mao W; Sun J; Wang J; Han G; Li C; Xia Y; Seesaha PK; Zhu D; Li H; Zhang J; Wang G; Wang X; Li X; Shu Y
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.
    Xia H; Zhang H; Ruan Z; Zhang H; Sun L; Chen H; Zhou Y; Zhang L; Bian D; Zhu X; Zhang J; Sun F; Yu H; Song N; Liu X; Zhu Y; Zhang H; He W; Chen J; Yang J; Chen G; Xie S; Tang D; Zhang X; Duan L; Zhao D; Li Q; Zhang P; Jiang G
    Signal Transduct Target Ther; 2024 Jun; 9(1):145. PubMed ID: 38871690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.
    Hao Y; Xie F; Zhou Y; Li C; Zhang X; Shen J; Yao M; Sun X; Zhou J; Wen T; Peng W
    Trials; 2024 Jul; 25(1):490. PubMed ID: 39030637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
    Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
    Mao L; Lian B; Li C; Bai X; Zhou L; Cui C; Chi Z; Sheng X; Wang X; Tang B; Yan X; Li S; Kong Y; Dai J; Wei X; Li J; Duan R; Xu H; Wu X; Yang Y; Cheng F; Zhang C; Xia F; Pang Z; Guo J; Si L
    JAMA Oncol; 2023 Aug; 9(8):1099-1107. PubMed ID: 37261804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
    Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
    BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
    Xu J; Shen J; Gu S; Zhang Y; Wu L; Wu J; Shao G; Zhang Y; Xu L; Yin T; Liu J; Ren Z; Xiong J; Mao X; Zhang L; Yang J; Li L; Chen X; Wang Z; Gu K; Chen X; Pan Z; Ma K; Zhou X; Yu Z; Li E; Yin G; Zhang X; Wang S; Wang Q
    Clin Cancer Res; 2021 Feb; 27(4):1003-1011. PubMed ID: 33087333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
    Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
    Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.